Impetigo Market Research Report By Severity (Mild, Moderate, Severe), By Treatment Type (Topical Antibiotics, Oral Antibiotics, Antiseptic Soaks), By Patient Age (Children, Adults, Elderly), By Causative Pathogen (Staphylococcus aureus, Streptococcus pyogenes, Other Bacteria) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2032

Impetigo Market Overview

As per MRFR analysis, the Impetigo Market Size was estimated at 3.05 (USD Billion) in 2022. The Impetigo Market Industry is expected to grow from 3.22(USD Billion) in 2023 to 5.2 (USD Billion) by 2032. The Impetigo Market CAGR (growth rate) is expected to be around 5.48% during the forecast period (2024 - 2032).

Key Impetigo Market Trends Highlighted

The most recent developments seen in the Impetigo market depict a growing trend toward prevention and the creation of new treatment options. The major drivers of the market include increasing incidences of impetigo in the developing regions, growing development of antibiotic resistance, and enhancing diagnostic capabilities. Market opportunities are open in the use of alternative antimicrobials, seeking effective vaccination approaches, and practice of preventive medicine. Furthermore, the enhanced use of telemedicine and mobile health technologies is creating new opportunities for remote patient management, as well as access to healthcare services in areas with scarce traditional medical practitioners.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Impetigo Market Drivers

Rising Prevalence of Skin Infections

Impetigo is one of the frequent bacterial skin infections due to bacteria, mainly Staphylococcus aureus and Streptococcus pyogenes. Increased incidence of skin infections among the general population, especially in developing and underdeveloped nations is one of the significant reasons contributing to the increased growth of the Global Impetigo Market Industry. Poor hygiene among the dense population, lack of access to pure water and hygienic conditions are also of the reasons for the spreading of skin infections, including impetigo among the individuals.The growing rates of skin infections can continue to comply the usage of impetigo treatment and care products thus encouraging market enlargement.

Advancements in Diagnostics and Therapeutics

Additionally, the Global Impetigo Market Industry is also fueled by the development in diagnostics and therapeutics. The rapid and accurate diagnosis of impetigo can facilitate timely detection and administration of the appropriate treatment; hence, improving patients’ outcomes and reducing the risk of complications. The introduction of the new antimicrobial agents that are targeted at the impetigo causing agent: bacteria has led to an efficacy of treatment and a reduction in the duration of the infection.

Growing Awareness and Education Initiatives

Increased awareness about impetigo and its prevention and treatment options is another major driver of the global impetigo market industry. Various public health campaigns are helping to create awareness among people about maintaining good hygiene practices, the significance of recognizing the early symptoms, and the importance of seeking early medical help. This leads to early diagnosis and early treatment of the infection, which reduces the severity of the infection and prevents complications.Educational programs are being held that educate and empower people to take preventive measures, thus, reducing the incidence of impetigo.

Impetigo Market Segment Insights

Impetigo Market Severity Insights

The Global Impetigo Market is segmented by severity into Mild, Moderate, and Severe. In 2023, the Mild segment accounted for the largest share of the market, with a revenue of USD 1.3 billion. The Moderate segment is expected to grow at the highest CAGR during the forecast period, with a CAGR of 6.1%. The severity of impetigo is determined by the depth of the skin lesions. Mild impetigo is characterized by superficial lesions that do not extend below the epidermis. Moderate impetigo is characterized by deeper lesions that extend into the dermis.Severe impetigo is characterized by lesions that extend into the subcutaneous tissue and may cause scarring. The incidence of impetigo is highest in children under the age of 10. The condition is more common in tropical and subtropical climates. Impetigo is spread through direct contact with infected skin or objects. The treatment of impetigo typically involves the use of topical antibiotics. In severe cases, oral antibiotics may be necessary. The growth of the market is being driven by the increasing incidence of impetigo, the development of new and more effective treatments, and the rising awareness of the condition.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Impetigo Market Treatment Type Insights

The three major treatment types for impetigo include topical antibiotics, oral antibiotics, and antiseptic soaks. Topical antibiotics are the most common treatment used to treat impetigo. Oral antibiotics are used for more severe cases of impetigo and when the infection has spread to other parts of the body. Antiseptic soaks are used to treat impetigo by cleaning the affected area and helping to prevent the infection from spreading. The Global Impetigo Market revenue for topical antibiotics is expected to be $245 Million by 2024. In comparison, the Global Impetigo Market revenue for oral antibiotics is estimated to be $180 Million by 2024.The Global Impetigo Market revenue for antiseptic soaks is expected to be $120 Million by 2024... The Global Impetigo Market is segmented by treatment type to provide a detailed overview of the Global Impetigo Market and its various segments. The data provided in this segmentation would be useful to make informed decisions about the development and marketing of new products and services in the Global Impetigo Market.

Impetigo Market Patient Age Insights

The Global Impetigo Market segmentation by Patient Age includes Children, Adults, and Elderly. Children are the most commonly affected age group, accounting for around 60% of all cases. This is due to their immature immune systems and frequent exposure to the bacteria that cause impetigo. Adults are less commonly affected, but they can still develop impetigo, especially if they have weakened immune systems or skin injuries. Elderly people are also at an increased risk of developing impetigo, as their skin is thinner and more fragile. The Global Impetigo Market revenue is expected to grow significantly in the coming years, driven by the increasing prevalence of impetigo and the development of new and more effective treatments.

Impetigo Market Causative Pathogen Insights

The Global Impetigo Market segmentation by Causative Pathogen comprises Staphylococcus aureus, Streptococcus pyogenes, and Other Bacteria. Staphylococcus aureus is the most prevalent causative pathogen, accounting for over 70% of Impetigo cases. Streptococcus pyogenes accounts for about 20-25% of cases, while Other Bacteria account for the remaining 5-10%. Staphylococcus aureus is a highly contagious bacteria that can cause a wide range of skin infections, including Impetigo. Streptococcus pyogenes is another bacteria that can cause Impetigo, and it is often associated with more severe infections.Other Bacteria that can cause Impetigo include Haemophilus influenzae, Escherichia coli, and Pseudomonas aeruginosa. These bacteria can cause Impetigo when they enter the skin through a break in the skin, such as a cut or scrape.

Impetigo Market Regional Insights

The Global Impetigo Market segmentation by region plays a crucial role in understanding the market dynamics and growth opportunities. North America holds a significant market share due to advanced healthcare infrastructure, high prevalence of skin infections, and increasing awareness about impetigo, with values of 1.11 billion USD in 2023 and expected to reach 1.796 billion USD by 2032. Europe follows closely, driven by similar factors and a growing elderly population susceptible to skin infections, with values of 0.925 billion USD in 2023 and expected to reach 1.496 billion USD by 2032. The APAC region is expected to witness substantial growth, owing to rising healthcare expenditure, increasing population, and expanding access to healthcare facilities, with values of 0.814 billion USD in 2023 and expected to reach 1.309 billion USD by 2032.South America and MEA are anticipated to contribute moderately to the overall market, with values of 0.185 billion USD in 2023 and expected to reach 0.299 billion USD by 2032 for South America, and 0.185 billion USD in 2023 and expected to reach 0.299 billion USD by 2032 for MEA, with emerging economies and improving healthcare systems presenting growth potential.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Impetigo Market Key Players And Competitive Insights

Major players in Impetigo Market industry are constantly striving to gain a competitive edge by developing innovative products and expanding their global reach. Leading Impetigo Market players are focusing on research and development to introduce new and improved treatments for impetigo. They are also expanding their product portfolios through acquisitions and collaborations to cater to the diverse needs of patients. The Impetigo Market is characterized by intense competition, with major players vying for market share through strategic partnerships, product differentiation, and aggressive marketing campaigns. The competitive landscape is expected to remain dynamic, with new entrants and emerging technologies shaping the future of the Impetigo Market.GlaxoSmithKline (GSK) is a leading player in the Impetigo Market, with a strong global presence and a diverse product portfolio. The company offers a range of topical and oral treatments for impetigo, including Bactroban, Fucidin, and Amoxicillin. GSK has a well-established distribution network and a strong sales force, which enables it to reach a wide customer base. The company is also actively involved in research and development, and has a number of new products in the pipeline for the treatment of impetigo.Pfizer is another major player in the Impetigo Market, with a strong focus on research and development. The company offers a range of topical and oral treatments for impetigo, including Zithromax, Keflex, and Bactrim. Pfizer has a strong global presence and a well-established distribution network. The company is also actively involved in clinical research, and has a number of new products in the pipeline for the treatment of impetigo.

Key Companies in the Impetigo Market Include

• Johnson Johnson


• Mylan N.V.


• Merck Sharp Dohme Corp.


• Galderma SA


• Cipla Ltd.


• Leo Pharma A/S


• Teva Pharmaceutical Industries Ltd.


• Sanofi S.A.


• Bayer AG


• Abbott Laboratories Inc.


• Novartis AG


• Amgen Inc.


• Almirall S.A.


• GlaxoSmithKline plc.


• Pfizer Inc.

Impetigo Market Industry Developments

The global impetigo market is expected to witness significant growth in the coming years, driven by factors such as the rising prevalence of skin infections, increasing awareness about the disease, and the development of new and effective treatment options. Geographically, the market is expected to be dominated by North America, followed by Europe and Asia-Pacific. Some of the key recent developments in the market include the approval of new antibiotics for the treatment of impetigo and the launch of new diagnostic tools. Major players in the market include GlaxoSmithKline, Pfizer, and Merck.

Impetigo Market Segmentation Insights

Impetigo Market Severity Outlook

• Mild


• Moderate


• Severe

Impetigo Market Treatment Type Outlook

• Topical Antibiotics


• Oral Antibiotics


• Antiseptic Soaks

Impetigo Market Patient Age Outlook

• Children


• Adults


• Elderly

Impetigo Market Causative Pathogen Outlook

• Staphylococcus aureus


• Streptococcus pyogenes


• Other Bacteria

Impetigo Market Regional Outlook

• North America


• Europe


• South America


• Asia Pacific


• Middle East and Africa